also demonstrated increased expression of the inhibitory receptor NKG2A in AML patients, and showed overexpression of NKG2A in NK cells correlated with failure to achieve remission, as well as impaired cytotoxicity against autologous blasts and leukemic cell lines (63). The gene discussed is KLRC1; the disease is acute myeloid leukemia.